CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Sebacia
Sebacia logo

Sebacia

Sebacia, Inc.: A Georgia-based medical device company innovating topical therapies for widespread dermatological conditions.

Duluth, GA, US🇺🇸
Founded
2010
Overview
Compare
Fundraising
Employees
Library

Founded in Georgia, Sebacia, Inc. is a private medical device company focused on developing innovative topical therapies for common dermatological conditions. The company's core mission is to offer superior alternatives to the conventional daily use of topical and systemic drugs, particularly for acne treatment. Sebacia leverages patented microparticles technology initially invented at Rice University and further refined in collaboration with dermatological researchers.

Sebacia has garnered attention for its groundbreaking approach to acne treatment, attracting notable investors and partnerships within the medical and dermatological fields. The company’s key achievements include securing patents for its unique microparticles technology and advancing clinical research to validate its efficacy. Sebacia's impact lies in its potential to revolutionize acne treatment, providing millions of sufferers with more effective and less invasive options.

Sebacia - Similar Companies

Accure Acne logo

Accure Acne

accureacne.com

Accuitis logo

Accuitis

accuitis.com

Neosil logo

Neosil

neosil.com

DermBiont logo

DermBiont

dermbiont.com

Skinomics logo

Skinomics

Microneb logo

Microneb

microneb.com

Respiderm logo

Respiderm

Stimusil logo

Stimusil

stimusil.com

Blossom Innovations logo

Blossom Innovations

Luma Therapeutics logo

Luma Therapeutics

Zitsticka logo

Zitsticka

zitsticka.com

Transport Pharmaceuticals logo

Transport Pharmaceuticals

Sonoma Pharmaceuticals logo

Sonoma Pharmaceuticals

sonomapharma.com

Micron Biomedical logo

Micron Biomedical

Medicreations logo

Medicreations

medicreations.com

Sebacia - Quick Facts

Who are Sebacia's competitors?

Companies similar to Sebacia include Accure Acne, Accuitis, Neosil and DermBiont.

When was Sebacia founded?

Sebacia was founded in 2010.

Where is Sebacia's headquarters located?

Sebacia's headquarters is located in Duluth, GA, US.

When was Sebacia's last funding round?

Sebacia's most recent funding round was for $10M (USD) in August 2019.

How much disclosed funding has Sebacia raised?

As of Aug 30, 2019, Sebacia has disclosed funding of $101.6M (USD). Undisclosed round amounts are excluded.

How many employees does Sebacia have?

Sebacia has 30 employees as of Feb 5, 2024.

Sebacia - Classification

Industry
  • Hardware
Ownership
  • Venture-backed
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Transactional
Customer
  • Consumers
Main Product
  • Medical Devices
Tags
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 16 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 325000Chemical Manufacturing
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 325410Pharmaceutical and Medicine Manufacturing
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 2830Drugs
  • 8730Research, Development, And Testing Services
  • 2834Pharmaceutical Preparations
  • 8731Commercial Physical and Biological Research